All posts by: Michael Zand

BRIEF-Cellectis is granted patent for CRISPR use in T-cells – Reuters

BRIEF-Cellectis is granted patent for CRISPR use in T-cellsReutersANNOUNCED ON MONDAY ABOUT THE GRANT BY THE EUROPEAN PATENT OFFICE OF PATENT NO. EP3004337 FOR THE INVENTION OF USING RNA-GUIDED ENDONUCLEASES, SUCH AS CAS9 OR CPF1 FOR THE GENETIC … Continue reading

Rosy future predicted for global synthetic biology industry – WhaTech

WhaTechRosy future predicted for global synthetic biology industryWhaTechThe top-down approach has been used to calculate the global synthetic biology market size by segment, and application. The market numbers for countries are obtained through top-do… Continue reading

Cellectis wins European patent for CRISPR use in T-cells – News-Medical.net

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina – Science Daily

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retinaScience DailyCRISPR-Cas9 is a powerful new technology that can target and edit certain aspects of the genome, or the complete set of genetic material of an organism. In the Nature Commu… Continue reading

Merck immunotherapy fails to improve survival in head and neck cancer – Reuters

Merck immunotherapy fails to improve survival in head and neck cancerReuters(Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than … Continue reading

Merck immunotherapy fails to improve survival in head and neck cancer – Reuters

Telegraph.co.ukMerck immunotherapy fails to improve survival in head and neck cancerReuters(Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck ca… Continue reading